Loading...
Market
Which therapy will lead the market share for sickle cell treatment by end of 2025?
2
Resolution / Starting Odds
BEAM-101 leads • 33%
Reni-cel leads • 33%
Casgevy leads • 33%
Market analysis reports from reputable financial or healthcare analysts
Story
Beam Therapeutics' BEAM-101 Shows Superior Results at ASH 2024, Stock Rises
Dec 9, 2024, 12:57 PM
Beam Therapeutics Inc. has reported promising clinical data for its sickle cell gene therapy, BEAM-101, at the American Society of Hematology (ASH) 2024 conference. The therapy has shown an average of 64-65% fetal hemoglobin (HbF) levels in patients, significantly higher than its competitors Reni-cel and Casgevy. BEAM-101's efficient manufacturing process allows for fewer mobilization cycles, with an average of 1.4 cycles, compared to Reni-cel's 4.6 and Casgevy's 4.7. This efficiency could potentially expand the eligible patient population for gene editing therapies. Additionally, Beam's approach includes a novel conditioning regimen using an anti-CD117 antibody, aiming to reduce toxicity and increase the feasibility of the treatment. The company's stock saw a 6.5% increase following the announcement, reflecting positive market sentiment towards the potential of BEAM-101.
View original story
Similar markets
Less than 10% • 25%
10% to 30% • 25%
30% to 50% • 25%
More than 50% • 25%
CRISPR Therapeutics • 25%
Intellia Therapeutics • 25%
Beam Therapeutics • 25%
Other • 25%
Afami-cel • 25%
Cosibelimab • 25%
Adagrasib-Cetuximab • 25%
Other • 25%
Apitegromab • 25%
Evrysdi • 25%
Spinraza • 25%
Other • 25%
Aucatzyl (Autolus Therapeutics) • 25%
Kymriah (Novartis) • 25%
Yescarta (Gilead) • 25%
Other • 25%
Successful • 25%
Partially Successful • 25%
Unsuccessful • 25%
No Data Released • 25%
Less than 1% • 25%
1% to 5% • 25%
5% to 10% • 25%
More than 10% • 25%
Gene therapy • 25%
Conventional drug therapy • 25%
Stem cell transplant • 25%
Other • 25%
Less than $500,000 • 25%
$500,000 to $750,000 • 25%
$750,000 to $1,000,000 • 25%
More than $1,000,000 • 25%
1-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
Editas Medicine • 25%
Intellia Therapeutics • 25%
CRISPR Therapeutics • 25%
Other • 25%
Pfizer • 25%
Roche • 25%
Novo Nordisk • 25%
Other • 25%